14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Buyers of assets typically like to pick and choose the assets and liabilities that they will acquire...
Read More >
Contracts form the backbone of all commercial transactions, and can be a useful instrument to safegu...
Read More >
On Dec. 20, 2019, the president signed into law the Setting Every Community Up for Retirement Enhanc...
Read More >
Seyfarth Synopsis: On December 23, 2019, District Judge Rosemary Marquez ruled, in connection with a...
Read More >
Building in part on amendments passed last year, the New York State Legislature has passed legislati...
Read More >
When a business acquires the assets of a unionized facility there are very few options for continuin...
Read More >